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Background: In December 2000, Medicare eliminated time limitations in immunosuppressant coverage after kidney
transplant for beneficiaries age ≥65 and those who were disabled. This change did not apply to younger non-
disabled beneficiaries who qualified for Medicare only because of their end-stage renal disease (ESRD). We sought
to examine access to waitlisting for kidney transplantation in a cohort spanning this policy change.
Methods: This was a retrospective cohort analysis of 241,150 Medicare beneficiaries in the United States Renal Data
System who initiated chronic dialysis between 1/1/96 and 11/30/03. We fit interrupted time series Cox proportional
hazard models to compare access to kidney transplant waitlist within 12 months of initiating chronic dialysis by
age/disability status, accounting for secular trends.
Results: Beneficiaries age <65 who were not disabled were less likely to be waitlisted after the policy change
(hazard ratio (HR) for the later vs. earlier period, 0.93, p = 0.002), after adjusting for sociodemographic factors,
co-morbid conditions, income, and ESRD network. There was no evidence of secular trend in this group (HR per
year, 1.00, p = 0.989). Likelihood of being waitlisted among those age ≥65 or disabled increased steadily throughout
the study period (HR per year, 1.04, p < 0.001), but was not clearly affected by the policy change (HR for the
immediate effect of policy change, 0.93, p = 0.135).
Conclusions: The most recent extension in Medicare immunosuppressant coverage appears to have had little
impact on the already increasing access to waitlisting among ≥65/ disabled beneficiaries eligible for the benefit but
may have decreased access for younger, non-disabled beneficiaries who were not. The potential ramifications of
policies on candidacy appeal for access to kidney transplantation should be considered.Background
Because demand for donor kidneys exceeds supply
several-fold [1], transplant centers are forced to make
difficult decisions about who should receive transplant-
able organs. Central to the long-standing debate on how
to allocate this scarce resource is the concept of equity—
equal utilization of resources for equal need [2]—as
women, the poor, and racial/ethnic minorities have his-
torically been less likely to receive transplants than men,
the wealthy, and non-Hispanic whites [3].
Health inequities may be influenced by policy [4].
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reproduction in any medium, provided the orprogram was established in 1973 rates of allograft sur-
vival were quite low. Therefore, immunosuppressant
coverage created by the Omnibus Reconciliation Act of
1986 was limited to 1 year and incrementally extended
to 3 years by mid-1995. In an effort to alleviate concerns
of senior citizens being unable to afford their medica-
tions, the Beneficiary Improvement and Protection Act
(BIPA) was passed in December 2000 to further extend
coverage to lifetime—but only for Medicare beneficiaries
whose eligibility was based on age or having a disability
other than end-stage renal disease (ESRD) [5].
Several studies have shown that transplant recipients
are at increased risk of medication noncompliance and
subsequent graft loss if they are not able to afford their
medications [6-8] and that incremental extensions in im-
munosuppressant coverage have been shown to have aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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showed that, while graft survival at 3 years post-
transplant was significantly lower for low- vs. high-
income kidney transplant recipients when coverage was
provided for only 1 year, there were no differences in
3-year graft survival by income when coverage was
extended to 3 years [9]. They found similar improvements
in graft survival among low-income recipients eligible for
lifetime coverage [10].
Given the association between graft survival and im-
munosuppressant coverage, it is possible that Medicare
immunosuppressant policy may also impact “upstream”
care processes such as listing for transplant. ESRD
patients without sufficient insurance coverage or finan-
cial resources may be viewed as less ideal transplant can-
didates and, therefore, may be less likely to be waitlisted.
Though older patients with ESRD and those with extra-
renal co-morbidities have historically been considered
less ideal candidates than younger patients and those
with fewer co-morbidities because of perceived surgical
risk and decreased transplant and patient survival [11-
19], the extension of lifetime immunosuppressant cover-
age to this group by BIPA may have increased their candi-
dacy appeal. Therefore, we hypothesized that expansion of
immunosuppressant coverage would differentially impact
access to waitlisting for kidney transplantation depending
on eligibility for it: with access increasing among older/
disabled beneficiaries who would always have insurance
coverage for immunosuppressants, but decreasing among
younger/non-disabled beneficiaries who might not be able
to afford their medications when Medicare eligibility
ended at three years post transplant and, therefore, be at
risk of rejecting a scarce resource. We sought to test this
hypothesis in a population of Medicare beneficiaries who




Using standard analysis files obtained with permission
from the United States Renal Data System (USRDS), a
national ESRD registry, we assembled a cohort of Medi-
care beneficiaries between the ages of 21 and 75 years
who initiated chronic dialysis between 1/1/96 and 11/30/
03. Individuals under 21 years were excluded from the
analysis because children are subject to a different selec-
tion algorithm for kidney transplant [20] and those
under 21 may have insurance coverage through their
parents. Individuals over 75 years were excluded because
this group receives <1% of all kidney transplants [13,21].
Beneficiaries who were waitlisted prior to initiating dia-
lysis were excluded because preemptive waitlisting
requires resources and early nephrology referral—factors
that vary by insurance status, income, and race [22,23]—and our goal was to assess the policy’s effect among uni-
formly resourced cohorts.
We limited our study to patients with Medicare as
their sole insurer using the payer variable at 90 days
post-dialysis initiation in the USRDS Core Payer History
file, which is compiled from a monthly record of pay-
ment source for ESRD service for each patient. Only
those with Medicare as primary payer were included.
Those with private insurance or dual coverage (Medicare
secondary payer, group health organization, or other)
were excluded because private forms of health insurance
have variable drug coverage and Medicaid immunosup-
pressant coverage varies across states. Patients were fol-
lowed starting at 90 days after initiation of dialysis
because patients under age 65 whose only entitlement to
Medicare is ESRD must wait 3 months on dialysis before
becoming eligible for Medicare. The cohort thus did not
include beneficiaries who died or received a kidney
transplant within the first 90 days after onset of ESRD.
Data source
The USRDS collects, analyzes, and distributes informa-
tion on all treated ESRD patients in the United States.
Data from the Patients file, the Medical Evidence file
and Transplant and Payer History files were merged to
create the final dataset. USRDS data also included par-
ticipant ZIP code of residence, which we used to assign
patients’ median ZIP code-level income according to the
2000 U.S. Population Census.
Primary predictors
Our primary predictors were age/disability status and
date of dialysis initiation. Disability was defined by em-
ployment status at time of dialysis initiation. Age and
disability status were used to create a dichotomous age/
disability status variable defined as age ≥65 years or dis-
abled or age <65 years and non-disabled. Those who met
Medicare eligibility for dialysis and were ≥65 years or
disabled were eligible for the lifetime immunosuppres-
sant benefit after 1/1/01.
Outcome variables
The primary outcome was access to kidney transplant-
ation, defined as time from day 91 after initiating
chronic dialysis (initial Medicare eligibility for dialysis)
to placement on the kidney transplant waitlist with cen-
soring at death or at 12 months after initial Medicare
eligibility for dialysis. Our 12-month time period is a
reasonable time period for patients to become accus-
tomed to dialysis and undergo kidney transplant evalu-
ation. The time period is consistent with Healthy People
2020 objectives for chronic kidney disease and is slightly
longer than that agreed upon by consensus in a study by
Ayanian et al. [24].





Waitlisted (n,%) 7,199 (9.4) 6,062 (3.7)
Mean age, years (SD) 50.5 (11.1) 65.0 (9.6)
Male (n,%) 39,808 (52.2) 87,910 (53.3))
Race/Ethnicity (n,%)
Non-Hispanic white 29,042 (38.1) 94,249 (57.1)
Non-Hispanic black 31,191 (40.9) 46,000 (27.9)
Hispanic 12,140 (15.9) 18,974 (11.5)
Other 3,855 (5.1) 5,699 (3.5)
Income quartile
>75th 18,451 (24.2) 47,156 (28.6)
50-75th 17,279 (22.7) 40,734 (24.7)
25-50th 18,383 (24.1) 40,029 (24.3)
<25th 22,115 (29.0) 37,003 (22.4)
Primary Cause ESRDb (n,%)
Diabetes 37,345 (49.0) 89,971 (54.6)
Hypertension 17,505 (23.0) 39,780 (24.1)
Glomerular 7,724 (10.1) 11,118 (6.7)
Cystic 1,569 (2.1) 2,448 (1.5)
Other/Unknown 12,085 (15.9) 21,605 (13.1)
Co-morbid Conditions (n,% with condition)
Congestive heart failure 18,501 (24.5) 61,259 (37.3)
Ischemic heart disease 10,961 (14.5) 48,848 (29.8)
Cerebrovascular accident 4,673 (6.2) 19,178 (11.7)
Peripheral vascular disease 7,634 (10.1) 30,571 (18.6)
Chronic obstructive
pulmonary disease
3,346 (4.4) 15,508 (9.4)
Tobacco abuse 6,088 (8.1) 9,693 (5.9)
Drug dependence 2,014 (2.7) 842 (0.5)
Cancer 1,994 (2.6) 9,880 (6.0)
HIV no AIDS 822 (1.7) 481 (0.4)
HIV with AIDS 1,383 (2.8) 2,408 (2.2)
Non-ambulatory 1,964 (2.6) 7,504 (4.6)
ap < 0.001 for all characteristics.
bESRD= end-stage renal disease.
cESRD networks not shown.
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Covariates included gender, race/ethnicity, income, pri-
mary cause of ESRD, co-morbid conditions at onset of
ESRD, and ESRD network. We defined race/ethnicity as
a categorical variable (non-Hispanic white (reference),
non-Hispanic Black, Hispanic, or Other). We defined
median ZIP code-level income in quartiles for the entire
sample. Primary causes of ESRD as a 6-category indica-
tor variable included diabetes (reference), hypertension,
glomerular disease, cystic renal disease, other/unknown
diagnosis. We adjusted our analyses using binary indica-
tors (no (reference)/yes) for the following co-morbid
conditions at the start of dialysis: congestive heart fail-
ure, ischemic heart disease, cerebrovascular accident,
peripheral vascular disease, chronic obstructive pulmon-
ary disease, tobacco abuse, drug dependence, and ability
to ambulate. HIV without or with AIDS was defined as a
three-level variable (no HIV/AIDS (reference)). We
included a categorical variable for all but one of the 18
ESRD networks to account for geographic variability in
access to renal transplant [25].
Statistical analyses
We fit interrupted time series (ITS) Cox proportional
hazard models to examine differential effects of the new
coverage policy on access to kidney transplant by age/
disability status, after adjusting for potential confoun-
ders. ITS is an established methodology that allows for
different secular trends before and after the introduction
of the new policy. This model accounts for the possibil-
ity that the intervention changes the trend, in which case
simple pre-post comparisons can be misleading [26-29].
For each age/disability group, the full ITS model allowed
for an abrupt change in the waitlisting rate at the begin-
ning of 2001, as well as for different secular trends be-
fore and after the introduction of the new policy. If no
statistically significant trends were found, we then sim-
plified the model by including only the potential con-
founders. We assumed patients who initiated dialysis in
2000 and completed one year of follow-up in 2001 were
affected by the new policy after 1/1/01; this was imple-
mented using time-dependent covariates. Results of this
model are summarized by plotting the estimated prob-
ability of being waitlisted within 12 months by group
and date of dialysis initiation, accounting for censoring
and holding all covariates constant at their sample
means; these calculations combined information from
the baseline survival function and adjusted relative hazard
estimates. All analyses were implemented in Stata Version
12.0 (Stata Corp., College Station, TX).
Results
There were 241,150 beneficiaries who met our study in-
clusion criteria and were included in the analysis. Ofthese, 76,228 (31.6%) were age <65/non-disabled and
164,922 (68.4%) were age ≥65/disabled. Patient charac-
teristics by age/disability status are shown in Table 1.
Those age ≥65/disabled were more likely to be non-
Hispanic white (Figure 1), live in a high-income ZIP
code, and have higher prevalent co-morbidities than
their age <65/non-disabled counterparts. The absolute
percentage of those waitlisted was higher among age


















% Age 65-75 years % Disabled 
non-Hispanic white non-Hispanic black Hispanic Other 
Figure 1 Age and disability status by race/ethnicity.
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waitlisting over the study period differed significantly be-
tween the age <65/non-disabled and age ≥65/disabled
groups (p < 0.001). However, as shown in Table 2, there
was no evidence for changes in the slope for likelihood
of waitlisting at the time of policy change (1/1/01)
within either group in the full ITS model (both
p > 0.350). In an intermediate model, which included
group-specific changes in likelihood of waitlisting at pol-
icy change and overall secular time trends across the en-
tire study period from January1998 through November
2003, there was no evident trend in the <65/non-disabled
group (HR per increase of 1 year, 1.00, 95% CI 0.98-1.02,
p = 0.989). In the final model, which omitted this non-
significant time trend, we found a substantial systematic
decrease in likelihood of waitlisting at the beginning of
2001 in the <65/non-disabled group (HR for theTable 2 Hazard ratios (HR) of waitlisting before policy change
difference in waitlisting, by age/disability status and year
Secular trend
Model Group Period HR
Full ITSa Model <65/non-disabled before policy change 1.0
after policy change 1.0
≥65/disabled before policy change 1.0
after policy change 1.0
Intermediate Model <65/non-disabled overall 1.0
≥65/disabled overall 1.0
Final Model <65/non-disabled - -
≥65/disabled overall 1.0
aITS = interrupted time series.
bP# = P-value for the equality of the within-group trends before and after policy chaimmediate effect of policy change, 0.93, 95% CI 0.89-
0.97, p = 0.002). In the ≥65/disabled group, we found
strong evidence for an increasing overall trend through-
out the study period (HR 1.04 per year, 1.02-1.07,
p < 0.001). There was a slight downward, but non-
statistically significant, change in the probability of
waitlisting at the beginning of 2001 (HR for the imme-
diate effect of policy change, 0.93, 0.85-1.02, p = 0.135),
after accounting for the significant time trend in the
≥65/disabled group. The adjusted probability of waitlisting
by age/disability status and quarter, as well as the time
trends based on the final model, are shown in Figure 2.
Those who were non-Hispanic black (vs. non-Hispanic
white), were female, or lived in a ZIP code-defined area
with lower income were less likely to be waitlisted
(Table 3). Additionally, those with comorbid illnesses or
disability were less likely to be waitlisted than their, after policy change (in 2001), and for the pre-/post-
Pre-post difference
95% CI P-value P#b HR 95% CI P-value
0 0.97-1.02 0.681 0.364 0.91 0.83-1.00 0.063
2 0.98-1.06 0.418
5 1.02-1.08 <0.001 0.515 0.94 0.85-1.04 0.220
3 0.99-1.08 0.123
0 0.98-1.02 0.989 - 0.93 0.85-1.01 0.099
4 1.02-1.07 <0.001 - 0.93 0.84-1.02 0.135
- - - 0.93 0.89-0.97 0.002



























1996 1997 1998 1999 2000 2001 2002 2003 2004
Year
age<65/non-disabled age>=65/disabled
Figure 2 Probability of waitlisting before and after policy change (in 2001) by age/disability status and quarter, adjusted for covariate
means. Lines represent estimated trends from final model of interrupted time series analysis.
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more likely (up to 3-fold) among those with a primary
cause of ESRD other than diabetes.
Discussion
We expected that the most recent extension of Medicare
immunosuppressant coverage would increase waitlisting
among older/disabled beneficiaries who would always
have insurance coverage for immunosuppressants, but
would decrease waitlisting among younger/non-disabled
beneficiaries who might not be able to afford their medi-
cations when Medicare eligibility ended at 3 years post
transplant. After accounting for existing secular trends
in waitlisting in a large national database, we found that
the policy change did not appear to affect the already in-
creasing access to the kidney transplant waitlist for the
older/disabled beneficiaries, but did appear to decrease
access for the younger/non-disabled beneficiaries.
While there is no absolute limit to the number of can-
didates who can be placed on the kidney transplant wait-
list, the waitlist is restricted to those candidates transplant
centers deem appropriate to receive the limited supply of
transplantable organs. Historically, older kidney transplant
candidates and those with extra-renal co-morbidities have
been considered less ideal transplantation candidates, due
to presumed reduced post-transplant functioning and sur-
vival [11-18]. Because transplant recipients who are un-
able to afford their medications are at increased risk of
medication noncompliance and subsequent graft loss
[6-8], it is conceivable that the extension of lifetime im-
munosuppressant coverage to ≥65/disabled Medicare
beneficiaries would improve this group’s transplantcandidacy appeal but would lessen that of younger/non-
disabled patients with limited drug coverage, despite
generally better overall health status. In other words, in
anticipation of which patients will best care for the lim-
ited pool of deceased donor kidneys, transplant pro-
grams may be more inclined to waitlist older/disabled
Medicare beneficiaries since the implementation of life-
time immunosuppressant coverage, but less inclined to
waitlist the younger/non-disabled candidates who would
lose Medicare coverage 3 years after transplant. Our
findings of decreased waitlisting among the younger/
non-disabled group after the policy change and increas-
ingly lower likelihood of waitlisting with lower area in-
come category support this assertion. This assertion is
further supported by a recent study finding that most
(67.3%) U.S. transplant programs report that they fre-
quently or occasionally do not waitlist patients who are
perceived to be unable to afford their immunosuppres-
sant medications [30].
Historically, the explicit rationale for differentiating
between those with and without existing Medicare eligi-
bility was that those under age 65 and disabled only be-
cause of ESRD were expected to return to work because
successful transplant was considered ‘rehabilitation’ [31].
However, return to work is uncommon post-transplant,
especially among recipients not working prior to trans-
plant, due to functional limitations and poor health sta-
tus [32,33]; and finding work that provides private
insurance is even less common [34].
Further, legislation for immunosuppressant coverage
was established when post-transplant drugs were consid-
ered by some to be experimental, and 1-year graft
Table 3 Hazard ratios (HR) of covariates, final modela
HR 95% CI P-value
Gender
Male 1.0
Female 0.75 0.72-0.78 <0.001
Race/ethnicity
Non-Hispanic white 1.0
Non-Hispanic black 0.82 0.78-0.86 <0.001
Hispanic 1.16 1.09-1.22 <0.001
Other 1.25 1.16-1.35 <0.001
ZIP code-level income quartile
>75th percentile 1.0
50-75th percentile 0.90 0.86-0.95 <0.001
25-50th percentile 0.85 0.81-0.89 <0.001
<25th percentile 0.72 0.68-0.76 <0.001
Primary cause of ESRD
Diabetes 1.0
Hypertension 1.28 1.22-1.34 <0.001
Glomerular 2.50 2.38-2.62 <0.001
Cystic 2.99 2.75-3.24 <0.001
Other 1.37 1.29-1.45 <0.001
Unknown 1.46 1.33-1.61 <0.001
Co-morbid conditionsb
Congestive heart failure 0.59 0.56-0.62 <0.001
Ischemic heart disease 0.68 0.64-0.72 <0.001
Cerebrovascular accident 0.60 0.54-0.65 <0.001
Peripheral vascular disease 0.68 0.63-0.73 <0.001
Chronic obstructive pulmonary disease 0.47 0.42-0.53 <0.001
Tobacco abuse 0.84 0.78-0.91 <0.001
Drug dependence 0.35 0.29-0.39 <0.001
Cancer 0.33 0.29-0.39 <0.001
HIV no AIDS 0.09 0.04-0.18 <0.001
HIV with AIDS 0.65 0.54-0.78 <0.001
Non-ambulatory 0.32 0.26-0.39 <0.001
aESRD networks not shown.
bReference = no condition.
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year survival is upward of 80% and is associated with
better quality of life than dialysis, transplantation has be-
come the preferred treatment for ESRD [36]. Several
studies have shown that, despite the significant cost of
transplantation itself, post-transplant care and immuno-
suppressants, transplantation is more cost-effective than
dialysis [5,35,36]. While Medicare spends a total of
$73,008 and $53,446 per patient year of hemodialysis
and peritoneal dialysis, respectively, only $24,572 per pa-
tient year is spent on kidney transplant [37]. Because
Medicare resumes dialysis payments after transplantgraft failure—which may be precipitated by limited
coverage for immunosuppressant medications—current
policy may be creating greater expense for the Medicare
program through excess return to dialysis among <65/
non-disabled patients. Our findings should be consid-
ered within the context of cost-effectiveness for the
Medicare program, the primary payer for dialysis and
transplantation in this country, and as part of the on-
going health care reform debate.
Because racial/ethnic minority ESRD patients are dis-
proportionately younger and non-disabled than non-
Hispanic whites, minorities may more often suffer
decreased access under current policy. We found that
non-Hispanic blacks in particular (but not other minor-
ities) were less likely to be waitlisted than non-Hispanic
whites. As evidenced in our study, racial/ethnic minor-
ities are more likely to develop ESRD at a younger age
than their non-Hispanic white counterparts [38-40] and
are therefore further from aging into Medicare eligibility.
Limitations
Our study is not without limitations. Disability status
was determined from the employment status variable.
Information regarding underlying cause of disability was
not available. Therefore, we were not able to differenti-
ate between disability status due to ESRD and disability
for another reason, which may have significantly inflated
proportions truly eligible for unlimited immunosuppres-
sant coverage fulfilled by the criterion disability not due
to ESRD. This misclassification may have been most
pronounced among minority patients given their
younger age at ESRD onset, increasing the likelihood
that their disability was ESRD-related. However, the
likely effect of this misclassification would be to attenu-
ate the observed relationship between policy change and
the likelihood of waitlisting among ≥65/disabled versus
<65/non-disabled patients. Thus, the true impact of the
policy on access to transplantation may be underesti-
mated. Additionally, some patients may have obtained
private insurance after 90 days of initiating dialysis
(when we defined insurance status); however, we expect
this is very low in our 12-month observation period
given the “pre-existing condition” of end-stage renal dis-
ease, which likely excluded many patients at that time
from affordable private insurance plans.
It is also possible that factors other than the policy
change are also contributing to the observed trends in
waitlisting of the ≥65/disabled population compared to
the <65/non-disabled population. For example, provider
attitudes regarding an upper age limit for transplantation
could have changed over time in favor of older appli-
cants, independent of the availability of lifetime im-
munosuppressant coverage. Also, the implementation of
policy for acceptance of expanded criteria donor (ECD)
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in observed rates [41]; however, there was only a 15% in-
crease in the number of ECD transplants [42] during
this study period, and not all ECD kidneys go to the
≥65/disabled population [43]. Anticipation of the policy
change could also be contributing to the steady increase
over time in likelihood of waitlisting for the ≥65/disabled
group—a finding that may reflect increasing patient and
provider awareness of the policy and its ramifications.
Such possibilities could not be examined here, given the
limitations of the data, but future studies examining
more recent trends in waitlisting, as well as reasons for
waitlisting or not waitlisting potential transplant candi-
dates, may help elucidate underlying causes.
Lastly, we recognize that waitlisting is but one step in
access to kidney transplantation. Many factors, such as
blood type and pre-formed antibodies, are important
determinants of receiving a kidney transplant. Because
these factors are only routinely measured in waitlisted
candidates, they were largely missing in our dataset, ren-
dering us unable to test our hypothesis in the entire
ESRD population.
Conclusions
In summary, our study suggests that the most recent
Medicare coverage extension did not appear to change the
already increasing access to the kidney transplant waitlist
for the ≥65/ disabled beneficiaries eligible for the benefit
but may have decreased access for the <65/non-disabled
beneficiaries who were not. Therefore, the potential rami-
fications of policies on candidacy appeal for access to
kidney transplantation should be considered.
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